MA52206A - Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels - Google Patents

Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels

Info

Publication number
MA52206A
MA52206A MA052206A MA52206A MA52206A MA 52206 A MA52206 A MA 52206A MA 052206 A MA052206 A MA 052206A MA 52206 A MA52206 A MA 52206A MA 52206 A MA52206 A MA 52206A
Authority
MA
Morocco
Prior art keywords
natural nkg2d
receptors
ligands binding
natural
modified domains
Prior art date
Application number
MA052206A
Other languages
English (en)
Inventor
Kaman C Kim
Kyle E Landgraf
Original Assignee
Xyphos Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xyphos Biosciences Inc filed Critical Xyphos Biosciences Inc
Publication of MA52206A publication Critical patent/MA52206A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA052206A 2018-03-27 2019-03-27 Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels MA52206A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862648636P 2018-03-27 2018-03-27

Publications (1)

Publication Number Publication Date
MA52206A true MA52206A (fr) 2021-02-17

Family

ID=66286967

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052206A MA52206A (fr) 2018-03-27 2019-03-27 Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels

Country Status (16)

Country Link
US (1) US20190300594A1 (fr)
EP (1) EP3774873A1 (fr)
JP (2) JP7443240B2 (fr)
KR (1) KR20200138311A (fr)
CN (1) CN112074532A (fr)
AU (1) AU2019243703B2 (fr)
BR (1) BR112020019336A2 (fr)
CA (1) CA3093967A1 (fr)
CO (1) CO2020013140A2 (fr)
IL (1) IL277339A (fr)
JO (1) JOP20200234A1 (fr)
MA (1) MA52206A (fr)
MX (1) MX2020010003A (fr)
PH (1) PH12020551554A1 (fr)
SG (1) SG11202009234QA (fr)
WO (1) WO2019191243A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178896A1 (fr) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anticorps anti-glyco-cd44 et leurs utilisations
CN111471099B (zh) * 2020-03-31 2022-04-12 长沙学院 MICA胞外区突变体及其筛选的方法、scFv-MICA融合抗体及其制备方法和应用
WO2022187591A1 (fr) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anticorps anti-glyco-cd44 et leurs utilisations
IL307945A (en) 2021-06-08 2023-12-01 Xyphos Biosciences Inc NKG2D antibody-ligand region fusion protein
CN117412988A (zh) 2021-06-08 2024-01-16 修普霍斯生物科学有限公司 抗体-nkg2d配体结构域融合蛋白
CA3228178A1 (fr) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anticorps anti-glyco-muc4 et leurs utilisations
KR20240109604A (ko) 2021-09-03 2024-07-11 고 테라퓨틱스, 인크. 항-글리코-cMET 항체 및 그의 용도
CA3230933A1 (fr) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anticorps anti-glyco-lamp1 et leurs utilisations
WO2024167898A1 (fr) 2023-02-07 2024-08-15 Go Therapeutics, Inc. PROTÉINES DE FUSION D'ANTICORPS COMPRENANT DES ANTICORPS ANTI-GLYCO-MUC4 ET DES DOMAINES α1-α2 DE PROTÉINE MIC, ET LEURS UTILISATIONS
WO2024167875A1 (fr) 2023-02-07 2024-08-15 Xyphos Biosciences Inc. Récepteur antigénique chimérique et protéine de fusion de domaine ligand nkg2d anticorps

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP3331912B1 (fr) * 2015-08-04 2024-05-01 Xyphos Biosciences Inc. Fragments d'anticorps variables et insérables et domaines a1-a2 modifiés de ligands de nkg2d, et ligands non naturels de nkg2d qui se lient à des récepteurs nkg2d non naturels
WO2020159941A1 (fr) * 2019-01-28 2020-08-06 Xyphos Biosciences Inc. Ligands de nkg2d non naturels modifiés administrant sélectivement des molécules hétérologues attachées à des récepteurs nkg2d non naturels sur des cellules car

Also Published As

Publication number Publication date
US20190300594A1 (en) 2019-10-03
PH12020551554A1 (en) 2021-06-07
WO2019191243A1 (fr) 2019-10-03
SG11202009234QA (en) 2020-10-29
EP3774873A1 (fr) 2021-02-17
BR112020019336A2 (pt) 2021-01-05
CN112074532A (zh) 2020-12-11
JP7443240B2 (ja) 2024-03-05
IL277339A (en) 2020-10-29
CO2020013140A2 (es) 2021-01-18
CA3093967A1 (fr) 2019-10-03
AU2019243703A1 (en) 2020-10-08
MX2020010003A (es) 2021-01-15
RU2020134984A (ru) 2022-04-27
KR20200138311A (ko) 2020-12-09
JP2024023230A (ja) 2024-02-21
AU2019243703B2 (en) 2024-07-25
JOP20200234A1 (ar) 2020-09-15
JP2021519287A (ja) 2021-08-10

Similar Documents

Publication Publication Date Title
MA52206A (fr) Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels
MA54514A (fr) Anticorps se liant à cd3
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
MA42060A (fr) Domaines de type iii de fibronectines fixant l'antigène membranaire spécifique de la prostate
DK3428274T3 (da) Anvendelse af nukleosominteragerende proteindomæner til forbedring af målrettet genommodifikation
MA49038A (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
MA45186A (fr) Domaines de fibronectine de type iii se liant à l'albumine sérique
DK3331912T3 (da) Indsættelige variable fragmenter af antistoffer og modificerede a1-a2-domæner af nkg2d-ligander og ikke-naturlige nkg2d-ligander, der binder ikke-naturlige nkg2d-receptorer
DK3242890T3 (da) Agonistiske tnf-receptor-bindingsmidler
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
MA45680A (fr) Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123
MA53616A (fr) Protéines bispécifiques modifiées
MA51649A (fr) Culture de placenta pour isoler des exosomes
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
MA43817A (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
DK3046420T3 (da) Forbedret fremgangsmåde til humanisering af animalsk skummetmælk
MA45185A (fr) Composé de sulfonamide ou son sel
ES2980503T3 (es) Material alternativo al cuero
SG11202101152QA (en) Antigen-binding molecule containing two antigen-binding domains that are linked to each other
DK3729255T3 (da) Mapning af entiteter til konti
MA51302A (fr) Anticorps se liant à hla-a2/wt1
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
DK3830132T5 (da) Humaniserede antistoffer mod psma
MA46523A (fr) Procédés de criblage de modulateurs d'une activité biologique de type gdf15
MA53498A (fr) Production de protéines recombinantes